Skip to main content
Clinical Trials/CTRI/2019/09/021317
CTRI/2019/09/021317
Completed
未知

Evaluation of genotyping and therapeutic drug monitoring vs. only therapeutic drug monitoring as a strategy for risk minimization in epileptic patients on phenytoin therapy: a randomized controlled trial

Dr Nithya Gogtay0 sites50 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: G403- Generalized idiopathic epilepsy and epileptic syndromes
Sponsor
Dr Nithya Gogtay
Enrollment
50
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
May 6, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Nithya Gogtay

Eligibility Criteria

Inclusion Criteria

  • i) Patients diagnosed with epilepsy ii) Patients on phenytoin therapy for at least 3 months duration
  • iii) Patients complaining of any ADRs to phenytoin like giddiness, headache, etc.

Exclusion Criteria

  • i) Patients with epilepsy on phenytoin therapy and are not willing to participate in the study
  • ii) Genotype (CYP2C9 and CYP2C19 polymorphism) results known to participant from prior testing or available in medical record
  • iii) Patients with neurological deficits
  • iv) Patients with history of drug /alcohol abuse

Outcomes

Primary Outcomes

Not specified

Similar Trials